Maravai LifeSciences Holdings, Inc. (MRVI)
NASDAQ: MRVI · Real-Time Price · USD
3.620
-0.020 (-0.55%)
Nov 28, 2025, 1:00 PM EST - Market closed
MRVI Stock Forecast
Stock Price Forecast
The 7 analysts that cover MRVI stock have a consensus rating of "Buy" and an average price target of $4.54, which forecasts a 25.41% increase in the stock price over the next year. The lowest target is $2.00 and the highest is $8.00.
Price Target: $4.54 (+25.41%)
Analyst Consensus: Buy
* Price targets were last updated on Aug 12, 2025.
Analyst Ratings
The average analyst rating for MRVI stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Hold | 5 | 5 | 5 | 5 | 5 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 10 | 10 | 10 | 10 | 10 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Craig-Hallum | Craig-Hallum | Strong Buy Maintains $10 → $5 | Strong Buy | Maintains | $10 → $5 | +38.12% | Aug 12, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $7 → $5 | Buy | Maintains | $7 → $5 | +38.12% | Aug 12, 2025 |
| Craig-Hallum | Craig-Hallum | Strong Buy Maintains $12 → $10 | Strong Buy | Maintains | $12 → $10 | +176.24% | May 13, 2025 |
| Baird | Baird | Hold Maintains $3 → $2 | Hold | Maintains | $3 → $2 | -44.75% | May 13, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $7 → $5 | Hold | Maintains | $7 → $5 | +38.12% | Mar 25, 2025 |
Financial Forecast
Revenue This Year
195.80M
from 259.19M
Decreased by -24.46%
Revenue Next Year
210.04M
from 195.80M
Increased by 7.27%
EPS This Year
-0.32
from -1.05
EPS Next Year
-0.21
from -0.32
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 213.7M | 234.2M | ||||
| Avg | 195.8M | 210.0M | ||||
| Low | 181.7M | 188.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -17.6% | 19.6% | ||||
| Avg | -24.5% | 7.3% | ||||
| Low | -29.9% | -3.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.24 | -0.12 | |||
| Avg | -0.32 | -0.21 | |||
| Low | -0.38 | -0.34 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.